AAVs are becoming the leading viral vector in the development of gene-based advanced therapy medicinal products (ATMPs). Their success is due to their intrinsic properties: they are primarily non-integrating as they persist within cells as episomes, and have a broad tropism with eleven serotypes that have the ability to infect specific cell types. A major challenge today is manufacturing sufficient quantities of AAV in order to treat larger groups of patients. FectoVIR®-AAV is a novel class of animal free transfection reagent specifically developed for industrial scale production of recombinant AAV (rAAV) viral vectors in suspension HEK-293 cell types. FectoVIR®-AAV transfection reagent guarantees higher rAAV viral titers, improved flexibility and scalability for industrial scale manufacturing.

FectoVIR®-AAV transfection reagent is a novel chemical-based and animal-free transfection reagent that has been engineered to address the current limits in rAAV viral vector yields and industrial scalability. FectoVIR®-AAV transfection reagent is the outcome of an extensive development process in which candidates from our proprietary internal chemical library were tested in comparison to the gold standard for virus production, our PEIpro® transfection reagent. In comparison to PEIpro® and other competitors, FectoVIR®-AAV stands out with its unmatched performance for the production of rAAV viral vectors in suspension cell culture systems. FectoVIR®-AAV reproducibly improves substantially AAV production yield with up to a remarkable 10-fold increase compared to other competitors (PEImax)